Intralesional Bevacizumab Injection on Primary Pterygium
Information source: Khon Kaen University
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pterygium; Inflammation
Intervention: Intralesional injection of bevacizumab (Drug); Topical antihistamine and vasoconstrictor (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Khon Kaen University Official(s) and/or principal investigator(s): Olan Suwan-apichon, md, Principal Investigator, Affiliation: Khon Kaen University
Overall contact: Olan Suwan-apichon, MD, Phone: +66 43 348383, Email: osuwanapichon@hotmail.com
Summary
The purpose of this study is to evaluate that intralesional injection of bevacizumab on
primary pterygium can reduce the corneal pterygium area, inflammation, redness and other
symptoms.
Clinical Details
Official title: A Randomized Controlled Trial of Intralesional Bevacizumab Injection on Primary Pterygium: Preliminary Results
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Primary outcome: percentage of corneal pterygium area
Detailed description:
To evaluate the efficacy and safety of intralesional injection of bevacizumab on primary
pterygium treatment
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- primary pterygium
Exclusion Criteria:
- previous ocular surgery
Locations and Contacts
Olan Suwan-apichon, MD, Phone: +66 43 348383, Email: osuwanapichon@hotmail.com
Srinagarind Hospital, Mueng, Khon Kaen 40000, Thailand; Recruiting Olan Suwan-apichon, MD
Additional Information
Starting date: January 2009
Last updated: July 7, 2011
|